<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
[ ]
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 28, 2000
--------------
-----------------
ANTEX BIOLOGICS INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 0-20988 52-1563899
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
</TABLE>
300 PROFESSIONAL DRIVE
GAITHERSBURG, MARYLAND 20879
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (301) 590-0129
---------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 4. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANTS
Effective April 28, 2000, the Company's independent
accountants, PricewaterhouseCoopers LLP,resigned.
In its report letter dated February 26, 1999 on the Company's
calendar year 1998 financial statements, the report of PricewaterhouseCoopers
LLP contained an explanatory paragraph expressing substantial doubt about the
Company's ability to continue as a going concern. In its report letter dated
March 30, 2000 on the Company's calendar year 1999 financial statements, no such
explanatory paragraph was included by PricewaterhouseCoopers LLP.
During the last two calendar years, and to the date of resignation,
there were no disagreements with PricewaterhouseCoopers LLP on any matter of
accounting principle or practice, financial statement disclosure, or auditing
scope or procedure that, if not resolved to the satisfaction of
PricewaterhouseCoopers LLP, would have caused PricewaterhouseCoopers LLP to
refer to the matter in its report.
The Company has requested PricewaterhouseCoopers LLP to furnish it a
letter addressed to the Commission stating whether it agrees with the above
statements. A copy of that letter, dated May 5, 2000, is filed as Exhibit 1 to
this Form 8-K.
The Audit Committee of the Company is conducting a search for new
independent accountants.
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Antex Biologics Inc.
--------------------
(Registrant)
/S/GREGORY C. ZAKARIAN
----------------------
Name: Gregory C. Zakarian
Title: Vice President, Finance
May 5, 2000
-----------
(Date)
<PAGE> 1
Exhibit 1
[PricewaterhouseCoopers LLP Letterhead]
May 5, 2000
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Commissioners:
We have read the statements made by Antex Biologics Inc. (copy attached), which
we understand will be filed with the Commission, pursuant to Item 4 of Form 8-K,
as part of the Company's Form 8-K report dated May 5, 2000. We agree with the
statements concerning our Firm in such Form 8-K.
Very truly yours,
/s/PricewaterhouseCoopers LLP
- -----------------------------
PricewaterhouseCoopers LLP
